Loading…
Indaptus Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.1% over 5Y.
today you would have $17.56▼ -98.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.91 | $23.58 | $49.28 | $40.60 | |
| P/B | 1.6x | 2.0x | 2.6x | 1.2x | 0.5x |
| EPS | -$21.58 | -$45.08 | -$51.24 | -$48.44 | |
| ROE | -254.26% | -661.54% | -380.80% | -127.71% | -58.15% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| EQEquillium, Inc. | $2.39 | — | 2.7x | — | -58.98% | $151.55M |
| KRROKorro Bio, Inc. | $10.34 | — | 1.5x | — | -97.69% | $152.26M |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $7.88 | — | 1.4x | — | -95.58% | $152.31M |
| CDXSCodexis Inc | $1.38 |
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Company description provided by Yahoo Finance.
| — |
| 3.8x |
| — |
| -69.36% |
| $151.12M |
| TNYATenaya Therapeutics, Inc. | $0.68 | — | 2.2x | — | -121.86% | $152.97M |
| OKUROnKure Therapeutics, Inc. | $3.79 | — | 0.9x | — | -46.91% | $153.48M |